Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition

Boehringer IngelheimAs part of a three-year global initiative to identify and support the most promising solutions to challenging health problems around the world, Boehringer Ingelheim and Ashoka's Changemakers® announced the launch of the "Making More Health" Competition.

This worldwide competition invites the most innovative models and solutions that are transforming the field of health today.The competition will recognize and award US $10,000 to each of three winners whose solutions are working to achieve individual, family, and community well-being.

The Making More Health competition seeks solutions that work along the entire continuum of health, from prevention and lifestyle, to detection and treatment. Eligible entries include those that increase access to quality health services and treatment; promote prevention, early detection, and diagnosis; empower individuals, families, and communities to address their health issues; or target vulnerable and underserved populations. Entries will be accepted until September 21, 2011.

"The Making More Health competition reflects Boehringer Ingelheim's commitment to supporting leadership and innovation in healthcare and to improving health for individuals, families, and communities," said Jean Scheftsik de Szolnok, Vice-President Southern Europe for Boehringer Ingelheim. "By sourcing new approaches to healthcare delivery, the competition will contribute to ensuring a sustainable future in which good health for everyone is possible."

Participants can submit competition entries through the www.changemakers.com/morehealth website where they can discuss and share ideas about different approaches to health, comment on entries, and vote for winners. An expert panel of judges, including Dr. Andreas Barner, chairman of the board of managing directors for Boehringer Ingelheim and Aman Bhandari, senior advisor to the CTO at the US Department of Health and Human Services, will select a pool of finalists, and the Changemakers online community will vote to determine the three winning entries.

"We are excited about the opportunity our partnership with Boehringer Ingelheim has offered to tap the drive and creativity of changemakers from around the globe and make their solutions visible to all who are interested in finding them," said Diana Wells, president of Ashoka. "Boehringer Ingelheim is taking an important leadership role in the sector by recognizing the value that surfacing community solutions for health is critical to their core business."

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing, and marketing novel products of high therapeutic value for human and veterinary medicine.

Social responsibility is a core element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of its global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic values of all of Boehringer Ingelheim's endeavors.

About Ashoka's Changemakers
Ashoka's Changemakers is an online community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and scaling ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three-decade history and vision for an "Everyone a Changemaker" world by creating a place where the best ideas in social innovation can be shared, refined, and funded.

Most Popular Now

Novo Nordisk announces plans to transform its appr…

Novo Nordisk announced plans to restructure its Research & Development (R&D) organisation to accelerate the expansion and diversification of its pipeline across serious c...

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

World's largest Alzheimer's survey reveals most ad…

Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute (BAI), in association with Alzheimer's Disease International (ADI), announced results from the largest glob...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Discovery could explain failed clinical trials for…

Researchers at King's College London have discovered a vicious feedback loop underlying brain degeneration in Alzheimer's disease which may explain why so many drug trial...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

Aspirin found not to prolong healthy aging

Taking a low-dose aspirin daily does not prolong healthy living in older adults, according to findings from the ASPirin in Reducing Events in the Elderly (ASPREE) trial p...

The Lancet Respiratory Medicine publishes first Ph…

AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

Clinical gene discovery program solves 30 medical …

A table in a recently published paper tells the story of 30 families who have, sometimes after years of searching, finally received an answer about the condition that has...